TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1545-1551

  Pajares, M J ^a,b   Agorreta, J ^a,b   Salvo, E ^a,b   Behrens, C ^c   Wistuba, I I ^c   Montuenga, L M ^a,b   Pio, R ^b,c   Rouzaut, A ^b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

adjuvant therapy; lung carcinoma; prognosis; survival; TGFBI

Indexed keywords

PLATINUM; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INDUCED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PROGNOSIS; TEXAS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84896489980     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.33     Document Type: Article

References (36)

1. Aggarwal C, Somaiah N, Simon G (2010) Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw 8: 822-832.
2. Ahmed A, Mills A, Ibrahim AEK, Temple J, Blenkiron C, Vias M, Massie C, Iyer NG, McGeoch A, Crawford R, Nicke B, Downward J, Swanton C, Bell S, Earl H, Laskey R, Caldas C, Brenton J (2007) The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12: 514-527.
3. Altman D, McShane L, Sauerbrei W, Taube S (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 10: 51-51.
4. Becker J, Volland S, Noskova I, Schramm A, Schweigerer L, Wilting J (2008) Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion. Int J Oncol 32: 235-240.
5. Chang A (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71: 3-10.
6. Coate L, John T, Tsao M, Shepherd F (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10: 1001-1010.
7. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Che (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368: 1101-1110.
8. Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvise M, Salvo E, Lozano MD, Pio R, Gil-Bazo I, Rouzaut A (2010) TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer 9: 130.
9. Ivanov S, Ivanova A, Salnikow K, Timofeeva O, Subramaniam M, Lerman M (2008) Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun 370: 536-540.
10. Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS (2000) Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J Biol Chem 275: 30907-30915.
11. Kim J, Kim E, Liu D, Lee JJ, Solis L, Behrens C, Lippman S, Hong W, Wistuba I, Lee H (2012) Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118: 2454-2465.
12. Kim J, Kim S, Jeong H, Lee B, Choi J, Park R, Park J, Kim I (2003) RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene 22: 2045-2053.
13. Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R, Nita ME, Takagi T, Nakamura Y, Tsunoda T (2001) Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 61: 3544-3549.
14. Langer C, Besse B, Gualberto A, Brambilla E, Soria J (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28: 5311-5320.
15. Maus MKH, Mack P, Astrow S, Stephens C, Zeger G, Grimminger P, Hsiang J, Huang E, Li T, Lara P, Danenberg K, Gandara D (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8: 582-586.
16. Morand S, Buchillier V, Maurer F, Bonny C, Arsenijevic Y, Munier F, Schorderet D (2003) Induction of apoptosis in human corneal and HeLa cells by mutated BIGH3. Invest Ophthalmol Vis Sci 44: 2973-2979.
17. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717.
18. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, Ichinose Y (2006) Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg 5: 362-366.
19. Olaussen K, Dunant A, Fouret P, Brambilla E, Andr F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper H, Stahel R, Sabatier L, Pignon J, Tursz T, Le Chevalier T, Soria J (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
20. Pajares M, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano M, Brambilla E, Brambilla C, Wistuba I, Behrens C, Timsit J, Pio R, Field J, Montuenga L (2012) Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 30: 1129-1136.
21. Robinson L, Ruckdeschel J, Wagner H, Stevens C (2007) Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 243S-265S.
22. Rosell R, Danenberg K, Alberola V, Bepler G, Sanchez J, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318-1325.
23. Schneider D, Kleeff J, Berberat P, Zhu Z, Korc M, Friess H, Bchler M (2002) Induction and expression of betaig-h3 in pancreatic cancer cells. Biochim Biophys Acta 1588: 1-6.
24. Scott W, Howington J, Feigenberg S, Movsas B, Pisters K (2007) Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 234S-242S.
25. Shah J, Shao G, Hei T, Zhao Y (2008) Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer 8: 284-284.
26. Shao G, Berenguer J, Borczuk A, Powell C, Hei T, Zhao Y (2006) Epigenetic inactivation of Betaig-h3 gene in human cancer cells. Cancer Res 66: 4566-4573.
27. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
28. Thapa N, Lee BH, Kim IS (2007) TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol 39: 2183-2194.
29. Travis WD, Brambilla E, Müller-Hermelink H, Harris C (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon.
30. Wang T, Nelson R, Bogardus A, Grannis F (2010) Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116: 1518-1525.
31. Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK (2011) Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 128: 1570-1584.
32. Wen G, Partridge M, Li B, Hong M, Liao W, Cheng S, Zhao Y, Calaf G, Liu T, Zhou J, Zhang Z, Hei T (2011) TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells. Cancer Lett 308: 23-32.
33. Win T, Sharples L, Groves A, Ritchie A, Wells F, Laroche C (2008) Predicting survival in potentially curable lung cancer patients. Lung 186: 97-102.
34. Zhao Y, El Gabry M, Hei T (2006) Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog 45: 84-92.
35. Zhao Y, Piao C, Hei T (2002) Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 21: 7471-7477.
36. Zhao Y, Shao G, Piao C, Berenguer J, Hei T (2004) Down-regulation of Betaig-h3 gene is involved in the tumorigenesis in human bronchial epithelial cells induced by heavy-ion radiation. Radiat Res 162: 655-659.